Dignóstico y manejo clínico | 09 OCT 17

Enfermedad intestinal inflamatoria en niños

Actualización sobre presentación, diagnóstico y manejo de la enfermedad intestinal inflamatoria en niños
2
9
Autor/a: Stephanie B Oliveira, Iona M Monteiro BMJ 2017;357:j2083
INDICE:  1. Página 1 | 2.  Referencias bibliográficas
Referencias bibliográficas

1 Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn’s disease: a population-based cohort study. Gastroenterology 2008;135:1106-13.
doi:10.1053/j.gastro.2008.06.079 pmid:18692056.
2 Pigneur B, Seksik P, Viola S, et al. Natural history of Crohn’s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis 2010;16:953-61. doi:10.1002/ibd.21152 pmid:19834970.
3 Malmborg P, Grahnquist L, Lindholm J, Montgomery S, Hildebrand H. Increasing incidence of paediatric inflammatory bowel disease in northern Stockholm County, 2002-2007. J Pediatr Gastroenterol Nutr 2013;57:29-34. doi:10.1097/MPG.0b013e31828f21b4 pmid:23459320.
4 Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003;88:995-1000. doi:10.1136/adc.88.11.995 pmid:14612366.
5 Buderus S, Scholz D, Behrens R, et al. CEDATA-GPGE Study Group. Inflammatory bowel disease in pediatric patients: Characteristics of newly diagnosed patients from the CEDATA-GPGE Registry. Dtsch Arztebl Int 2015;112:121-7.pmid:25759978.
6 Day AS, Ledder O, Leach ST, Lemberg DA. Crohn’s and colitis in children and adolescents. World J Gastroenterol 2012;18:5862-9. doi:10.3748/wjg.v18.i41.5862 pmid:23139601.
7 Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011;17:423-39. doi:10.1002/ibd.21349 pmid:20564651.
8 Urlep D, Blagus R, Orel R. Incidence Trends and Geographical Variability of Pediatric Inflammatory Bowel Disease in Slovenia: A Nationwide Study. Biomed Res Int 2015; 2015:921730.
doi:10.1155/2015/921730 pmid:26688822.
9 El Mouzan MI, Saadah O, Al-Saleem K, et al. Incidence of pediatric inflammatory bowel disease in Saudi Arabia: a multicenter national study. Inflamm Bowel Dis 2014;20:1085-90.pmid:24788219.
10 Adamiak T, Walkiewicz-Jedrzejczak D, Fish D, et al. Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: a population-based epidemiological study. Inflamm Bowel Dis 2013;19:1218-23. doi:10.1097/MIB.0b013e318280b13e pmid:23528339. 
11 Chu HP, Logarajah V, Tan N, Phua KB. Paediatric inflammatory bowel disease in a multiracial Asian country. Singapore Med J 2013;54:201-5. doi:10.11622/smedj.2013073 pmid:23624446.
12 Agnarsson U, Bjornsson S, Johansson JH, Sigurdsson L. Inflammatory bowel disease in Icelandic children 1951-2010. Population-based study involving one nation over six decades. Scand J Gastroenterol 2013;48:1399-404. doi:10.3109/00365521.2013.845799 pmid:24164345.
13 Chouraki V, Savoye G, Dauchet L, et al. The changing pattern of Crohn’s disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007). Aliment Pharmacol Ther 2011;33:1133-42. doi:10.1111/j.1365-2036.2011.04628.x pmid:21488915.
14 Malaty HM, Fan X, Opekun AR, Thibodeaux C, Ferry GD. Rising incidence of inflammatory bowel disease among children: a 12-year study. J Pediatr Gastroenterol Nutr 2010;50:27-31. doi:10.1097/MPG.0b013e3181b99baa pmid:19934770.
15 Al-Qabandi WA, Buhamrah EK, Hamadi KA, Al-Osaimi SA, Al-Ruwayeh AA, Madda J. Inflammatory bowel disease in children, an evolving problem in Kuwait. Saudi J Gastroenterol 2011;17:323-7. doi:10.4103/1319-3767.84487 pmid:21912059.
16 Castro M, Papadatou B, Baldassare M, et al. Inflammatory bowel disease in children and adolescents in Italy: data from the pediatric national IBD register (1996-2003). Inflamm Bowel Dis 2008;14:1246-52. doi:10.1002/ibd.20470 pmid:18521916.
17 Jakobsen C, Wewer V, Urne F, et al. Incidence of ulcerative colitis and Crohn’s disease in Danish children: Still rising or levelling out? J Crohns Colitis 2008;2:152-7. doi:10.1016/j.crohns.2008.01.006 pmid:21172205.
18 Pinsk V, Lemberg DA, Grewal K, Barker CC, Schreiber RA, Jacobson K. Inflammatory bowel disease in the South Asian pediatric population of British Columbia. Am J Gastroenterol 2007;102:1077-83. doi:10.1111/j.1572-0241.2007.01124.x pmid:17378907.
19 Turunen P, Kolho KL, Auvinen A, Iltanen S, Huhtala H, Ashorn M. Incidence of inflammatory bowel disease in Finnish children, 1987-2003. Inflamm Bowel Dis 2006;12:677-83. doi:10.1097/00054725-200608000-00002 pmid:16917221.
20 Perminow G, Frigessi A, Rydning A, Nakstad B, Vatn MH. Incidence and clinical presentation of IBD in children: comparison between prospective and retrospective data in a selected Norwegian population. Scand J Gastroenterol 2006;41:1433-9. doi:10.1080/00365520600789891 pmid:17101574.
21 Pozler O, Maly J, Bonova O, et al. Incidence of Crohn disease in the Czech Republic in the years 1990 to 2001 and assessment of pediatric population with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2006; 42:186-9. doi:10.1097/01.mpg.0000189328.47150.bc pmid:16456413.
22 Armitage EL, Aldhous MC, Anderson N, et al. Incidence of juvenile onset Crohn’s disease in Scotland: association with northern latitude and affluence. Gastroenterology 2004;127:1051-7. doi:10.1053/j.gastro.2004.06.024 pmid:15480983.
23 Benchimol EI, Guttmann A, Griffiths AM, et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut 2009;58:1490-7. doi:10.1136/gut.2009.188383 pmid:19651626.
24 Henderson P, Hansen R, Cameron FL, et al. Rising incidence of pediatric inflammatory bowel disease in Scotland. Inflamm Bowel Dis 2012;18:999-1005. doi:10.1002/ibd.21797 pmid:21688352.
25 Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54.e42, quiz e30. doi:10.1053/j.gastro.2011.10.001 pmid:22001864.
26 Day AS, Lemberg DA, Gearry RB. Inflammatory bowel disease in australasian children and adolescents. Gastroenterol Res Pract 2014; 2014:703890. doi:10.1155/2014/703890 pmid:24799892.
27 Abramson O, Durant M, Mow W, et al. Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006.J Pediatr 2010;157:233-239.e1. doi:10.1016/j.jpeds.2010.02.024 pmid:20400099.
28 Kugathasan S, Judd RH, Hoffmann RG, et al. Wisconsin Pediatric Inflammatory Bowel Disease Alliance. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 2003;143:525-31. doi:10.1067/S0022-3476(03)00444-X pmid:14571234.
29 Jussila A, Virta LJ, Salomaa V, Maki J, Jula A, Farkkila MA. High and increasing prevalence of inflammatory bowel disease in Finland with a clear North-South difference. J Crohns Colitis 2013;7:e256-62. doi:10.1016/j.crohns.2012.10.007 pmid:23140840.
30 Burisch J, Pedersen N, Čuković-Čavka S, et al. EpiCom-group. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort.Gut 2014;63:588-97. doi:10.1136/gutjnl-2013-304636 pmid:23604131.
31 Liu JZ, van Sommeren S, Huang H, et al. International Multiple Sclerosis Genetics Consortium International IBD Genetics Consortium. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 2015;47:979-86. doi:10.1038/ng.3359 pmid:26192919.
32 Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut 2011;60:1739-53. doi:10.1136/gut.2009.199679 pmid:21300624.
33 Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol 2015;37:47-55. doi:10.1007/s00281-014-0454-4 pmid:25420450.
34 Ruemmele FM, Veres G, Kolho KL, et al. European Crohn’s and Colitis Organisation European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis 2014;8:1179-207. doi:10.1016/j.crohns.2014.04.005 pmid:24909831.
35 Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014;15:382-92. doi:10.1016/j.chom.2014.02.005 pmid:24629344.
36 Conte MP, Schippa S, Zamboni I, et al. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut 2006;55:1760-7. doi:10.1136/gut.2005.078824 pmid:16648155.
37 Strachan DP.Hay fever, hygiene, and household size. BMJ 1989;299:1259-60. doi:10.1136/bmj.299.6710.1259 pmid:2513902.
38 Cholapranee A, Ananthakrishnan AN. Environmental Hygiene and Risk of Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2016;22:2191-9. doi:10.1097/MIB.0000000000000852 pmid:27482977.
39 Kaistha A, Levine J. Inflammatory bowel disease: the classic gastrointestinal autoimmune disease. Curr Probl Pediatr Adolesc Health Care 2014; 44:328-34. 
doi:10.1016/j.cppeds.2014.10.003 pmid:25499459.
40 Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34. doi:10.1038/nature06005 pmid:17653185.
41 Baldassano RN, Bradfield JP, Monos DS, et al. Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn’s disease. Clin Gastroenterol Hepatol 2007;5:972-6. doi:10.1016/j.cgh.2007.04.024 pmid:17618837.
42 Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-3. doi:10.1126/science.1135245 pmid:17068223.
43 Weinstein TA, Levine M, Pettei MJ, Gold DM, Kessler BH, Levine JJ. Age and family history at presentation of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2003; 37:609-13. doi:10.1097/00005176-200311000-00020 pmid:14581806.
44 McDermott E, Ryan EJ, Tosetto M, et al. DNA Methylation Profiling in Inflammatory Bowel Disease Provides New Insights into Disease Pathogenesis. J Crohns Colitis 2016;10:77-86. doi:10.1093/ecco-jcc/jjv176 pmid:26419460.
45 Gasparetto M, Guariso G, Pozza LV, Ross A, Heuschkel R, Zilbauer M. Clinical course and outcomes of diagnosing Inflammatory Bowel Disease in children 10 years and under: retrospective cohort study from two tertiary centres in the United Kingdom and in Italy. BMC Gastroenterol 2016;16:35. doi:10.1186/s12876-016-0455-y pmid:26976427.
46 Gupta N, Bostrom AG, Kirschner BS, et al. Gender differences in presentation and course of disease in pediatric patients with Crohn disease. Pediatrics 2007;120:e1418-25. doi:10.1542/peds.2007-0905 pmid:18055660.
47 Uhlig HH, Schwerd T, Koletzko S, et al. COLORS in IBD Study Group and NEOPICS. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 2014;147:990-1007.e3. doi:10.1053/j.gastro.2014.07.023 pmid:25058236.
48 Oliva-Hemker M, Hutfless S, Al Kazzi ES, et al. Clinical Presentation and Five-Year Therapeutic Management of Very Early-Onset Inflammatory Bowel Disease in a Large North American Cohort. J Pediatr 2015;167:527-32.e1-3. doi:10.1016/j.jpeds.2015.04.045 pmid:25982142.
49 IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis–the Porto criteria. J Pediatr Gastroenterol Nutr 2005;41:1-7. doi:10.1097/01.
MPG.0000163736.30261.82 pmid:15990620.
50 Sabery N, Bass D. Use of serologic markers as a screening tool in inflammatory bowel disease compared with elevated erythrocyte sedimentation rate and anemia. Pediatrics 2007;119:e193-9.
doi:10.1542/peds.2006-1361 pmid:17158948.
51 Cabrera-Abreu JC, Davies P, Matek Z, Murphy MS. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child 2004;89:69-71.pmid:14709513.
52 Bloomfield MG, Balm MN, Blackmore TK. Molecular testing for viral and bacterial enteric pathogens: gold standard for viruses, but don’t let culture go just yet? Pathology 2015;47:227-33. doi:10.1097/PAT.0000000000000233 pmid:25719855.
53 Fagerberg UL, Loof L, Lindholm J, Hansson LO, Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;45:414-20. doi:10.1097/MPG.0b013e31810e75a9 pmid:18030206.
54 Holtman GA, Lisman-van Leeuwen Y, Reitsma JB, Berger MY. Noninvasive Tests for Inflammatory Bowel Disease: A Meta-analysis. Pediatrics 2016;137. doi:10.1542/peds.2015-2126 pmid:26681783.
55 Mack DR, Langton C, Markowitz J, et al. Pediatric Inflammatory Bowel Disease Collaborative Research Group. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics 2007;119:1113-9. doi:10.1542/peds.2006-1865 pmid:17545378.
56 Benor S, Russell GH, Silver M, Israel EJ, Yuan Q, Winter HS. Shortcomings of the inflammatory bowel disease Serology 7 panel. Pediatrics 2010;125:1230-6. doi:10.1542/peds.2009-1936 pmid:20439597.
57 Papp M, Lakatos PL. Serological studies in inflammatory bowel disease: how important are they? Curr Opin Gastroenterol 2014;30:359-64.
doi:10.1097/MOG.0000000000000076 pmid:24811052.
58 Amre DK, Lu SE, Costea F, Seidman EG. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn’s disease patients. Am J Gastroenterol 2006;101:645-52. doi:10.1111/j.1572-0241.2006.00468.x pmid:16464223.
59 Washington K, Greenson JK, Montgomery E, et al. Histopathology of ulcerative colitis in initial rectal biopsy in children. Am J Surg Pathol 2002;26:1441-9. doi:10.1097/00000478-200211000-00006 pmid:12409720.
60 Castellaneta SP, Afzal NA, Greenberg M, et al. Diagnostic role of upper gastrointestinal endoscopy in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004;39:257-61. doi:10.1097/00005176-200409000-00006 pmid:15319625.
61 Hummel TZ, ten Kate FJ, Reitsma JB, Benninga MA, Kindermann A. Additional value of upper GI tract endoscopy in the diagnostic assessment of childhood IBD. J Pediatr Gastroenterol Nutr 2012;54:753-7. doi:10.1097/MPG.0b013e318243e3e3 pmid:22584746.
62 Kovacs M, Muller KE, Arato A, et al. Hungarian IBD Registry Group (HUPIR). Diagnostic yield of upper endoscopy in paediatric patients with Crohn’s disease and ulcerative colitis. Subanalysis of the HUPIR registry. J Crohns Colitis 2012;6:86-94. doi:10.1016/j.crohns.2011.07.008 pmid:22261532.
63 Cohen SA, Klevens AI. Use of capsule endoscopy in diagnosis and management of pediatric patients, based on meta-analysis. Clin Gastroenterol Hepatol 2011; 9:490-6. doi:10.1016/j.cgh.2011.03.025 pmid:21440674.
64 Gralnek IM, Cohen SA, Ephrath H, et al. Small bowel capsule endoscopy impacts diagnosis and management of pediatric inflammatory bowel disease: a prospective study. Dig Dis Sci 2012;57:465-71. doi:10.1007/s10620-011-1894-5 pmid:21901253.
65 Min SB, Le-Carlson M, Singh N, et al. Video capsule endoscopy impacts decision making in pediatric IBD: a single tertiary care center experience. Inflamm Bowel Dis 2013; 19:2139-45. doi:10.1097/MIB.0b013e31829a749c pmid:23867872.
66 Bousvaros A, Antonioli DA, Colletti RB, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Colitis Foundation of America. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn’s and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007;44:653-74. doi:10.1097/MPG.0b013e31805563f3 pmid:17460505.
67 Anupindi SA, Podberesky DJ, Towbin AJ, et al. Pediatric inflammatory bowel disease: imaging issues with targeted solutions. Abdom Imaging 2015;40:975-92. doi:10.1007/s00261-015-0423-y pmid:25920487.
68 Anupindi SA, Grossman AB, Nimkin K, Mamula P, Gee MS. Imaging in the evaluation of the young patient with inflammatory bowel disease: what the gastroenterologist needs to know. J Pediatr Gastroenterol Nutr 2014;59:429-39. doi:10.1097/MPG.0000000000000475 pmid:24979661.
69 Horsthuis K, Bipat S, Bennink RJ, Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology 2008;247:64-79. doi:10.1148/radiol.2471070611 pmid:18372465.
70 Pant C, Deshpande A, Fraga-Lovejoy C, O’Connor J, Gilroy R, Olyaee M. Emergency Department Visits Related to Inflammatory Bowel Disease: Results From Nationwide Emergency Department Sample. J Pediatr Gastroenterol Nutr 2015;61:282-4.
doi:10.1097/MPG.0000000000000815 pmid:25859825.
71 Duigenan S, Gee MS. Imaging of pediatric patients with inflammatory bowel disease. AJR Am J Roentgenol 2012;199:907-15. doi:10.2214/AJR.11.7966 pmid:22997386.
72 Pallotta N, Tomei E, Viscido A, et al. Small intestine contrast ultrasonography: an alternative to radiology in the assessment of small bowel disease. Inflamm Bowel Dis 2005;11:146-53.
doi:10.1097/00054725-200502000-00008 pmid:15677908.
73 Giles E, Barclay AR, Chippington S, Wilson DC. Systematic review: MRI enterography for assessment of small bowel involvement in paediatric Crohn’s disease. Aliment Pharmacol Ther 2013;37:1121-31. doi:10.1111/apt.12323 pmid:23638954.
74 Essary B, Kim J, Anupindi S, Katz JA, Nimkin K. Pelvic MRI in children with Crohn disease and suspected perianal involvement. Pediatr Radiol 2007;37:201-8. doi:10.1007/s00247-006-0372-2 pmid:17180366.
75 Levine A, Koletzko S, Turner D, et al. European Society of Pediatric Gastroenterology, Hepatology, and Nutrition. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014;58:795-806.pmid:24231644.
76 Lahad A, Weiss B. Current therapy of pediatric Crohn’s disease. World J Gastrointest Pathophysiol 2015;6:33-42. doi:10.4291/wjgp.v6.i2.33 pmid:25977836.
77 Colombel JF, Sandborn WJ, Reinisch W, et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383-95. doi:10.1056/NEJMoa0904492 pmid:20393175.
78 Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol 2015;110:1324-38. doi:10.1038/ajg.2015.233 pmid:26303131.
79 Critch J, Day AS, Otley A, King-Moore C, Teitelbaum JE, Shashidhar H. NASPGHAN IBD Committee. Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2012;54:298-305. doi:10.1097/MPG.0b013e318235b397 pmid:22002478.
80 Gordon J, Ramaswami A, Beuttler M, et al. EBV Status and Thiopurine Use in Pediatric IBD. J Pediatr Gastroenterol Nutr 2016;62:711-4. doi:10.1097/MPG.0000000000001077 pmid:26655944.
81 Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004;2:309-13. doi:10.1016/S1542-3565(04)00060-6 pmid:15067625.
82 Escher JC, Taminiau JA, Nieuwenhuis EE, Buller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 2003;9:34-58. doi:10.1097/00054725-200301000-00006 pmid:12656136.
83 Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998;115:813-21. doi:10.1016/S0016-5085(98)70251-3 pmid:9753482.
84 Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32. doi:10.1053/j.gastro.2007.05.029 pmid:17681163.
85 Turner D, Travis SP, Griffiths AM, et al. European Crohn’s and Colitis Organization Porto IBD Working Group, European Society of Pediatric Gastroenterology, Hepatology, and Nutrition. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol 2011;106:574-88. doi:10.1038/ ajg.2010.481 pmid:21224839.
86 Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr 2012;55:93-108. doi:10.1097/MPG.0b013e31825959b8 pmid:22516861.
87 de Zoeten EF, Pasternak BA, Mattei P, Kramer RE, Kader HA. Diagnosis and treatment of perianal Crohn disease: NASPGHAN clinical report and consensus statement. J Pediatr Gastroenterol Nutr 2013;57:401-12. doi:10.1097/MPG.0b013e3182a025ee pmid:23974063.
88 Ardura MI, Toussi SS, Siegel JD, Lu Y, Bousvaros A, Crandall W. NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Inhibitors. J Pediatr Gastroenterol Nutr 2016;63:130-55. doi:10.1097/MPG.0000000000001188 pmid:27027903.
89 Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr 2000;31:8-15. doi:10.1097/00005176-200007000-00005 pmid:10896064.
90 Dziechciarz P, Horvath A, Shamir R, Szajewska H. Meta-analysis: enteral nutrition in active Crohn’s disease in children. Aliment Pharmacol Ther 2007;26:795-806. doi:10.1111/j.1365- 2036.2007.03431.x pmid:17767463.
91 Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006;4:744-53. doi:10.1016/j.cgh.2006.03.010 pmid:16682258.
92 Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47. doi:10.1097/00005176-199105000-00005 pmid:1678008.
93 Johnson T, Macdonald S, Hill SM, Thomas A, Murphy MS. Treatment of active Crohn’s disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut 2006;55:356-61. doi:10.1136/gut.2004.062554 pmid:16162683.
94 Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMXR extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
Gastroenterology 2012;143:1218-26.e1-2. doi:10.1053/j.gastro.2012.08.003 pmid:22892337.
95 Nitzan O, Elias M, Peretz A, Saliba W. Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol 2016;22:1078-87. doi:10.3748/wjg.v22.i3.1078 pmid:26811648.
96 Mesker T, van Rheenen PF, Norbruis OF, et al. Pediatric Crohn’s disease activity at diagnosis, its influence on pediatrician’s prescribing behavior, and clinical outcome 5 years later. Inflamm Bowel Dis 2009;15:1670-7. doi:10.1002/ibd.20950 pmid:19418567.
97 Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10:CD0 00543.pmid:23076889.
98 Zeisler B, Lerer T, Markowitz J, et al. Pediatric Inflammatory Bowel Disease Collaborative Research Group. Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis. J Pediatr Gastroenterol Nutr 2013;56:12-8. doi:10.1097/
MPG.0b013e31826ac41a pmid:22847466.
99 Cezard JP, Munck A, Mouterde O, et al. Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn’s disease: a multicenter, double-blind, randomized, placebo-controlled trial. Gastroenterol Clin Biol 2009;33:31-40. doi:10.1016/j.gcb.2008.07.007pmid:19118966.
100 Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev 2010;(12):CD008870.pmid:21154400.
101 Grossi V, Lerer T, Griffiths A, et al. Concomitant Use of Immunomodulators
Affects the Durability of Infliximab Therapy in Children With Crohn’s Disease. Clin Gastroenterol Hepatol 2015;13:1748-56. doi:10.1016/j.cgh.2015.04.010 pmid:25911120.
102 Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000;119:895-902. doi:10.1053/gast.2000.18144 pmid:11040176.
103 Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13. doi:10.1016/S0016-5085(00)70140-5 pmid:10734022.
104 Benkov K, Lu Y, Patel A, Rahhal R, Russell G, Teitelbaum J. NASPGHAN Committee on Inflammatory Bowel Disease. Role of thiopurine metabolite testing and thiopurine methyltransferase determination in pediatric IBD. J Pediatr Gastroenterol Nutr 2013;56:333-40. doi:10.1097/MPG.0b013e3182844705 pmid:23287804.
105 Scherkenbach LA, Stumpf JL. Methotrexate for the Management of Crohn’s Disease in Children. Ann Pharmacother 2016;50:60-9. doi:10.1177/1060028015613527 pmid:26511908.
106 Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn’s disease. Am J Gastroenterol 2007;102:2804-12, quiz 2803, 2813. doi:10.1111/j.1572-0241.2007.01474.x pmid:18042110.
107 Hyams J, Crandall W, Kugathasan S, et al. REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate to severe Crohn’s disease in children.Gastroenterology 2007;132:863-73, quiz 1165-6. doi:10.1053/j.gastro.2006.12.003 pmid:17324398.
108 Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology 2012;143:365-74.e2. doi:10.1053/j.gastro.2012.04.046 pmid:22562021.
109 Hyams J, Damaraju L, Blank M, et al. T72 Study Group. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2012;10:391-9.e1. doi:10.1016/j.cgh.2011.11.026 pmid:22155755.
110 Afif W, Loftus EV Jr, , Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:1133-9. doi:10.1038/ajg.2010.9 pmid:20145610.
111 Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012;10:1079-87, quiz e85-6. doi:10.1016/j.cgh.2012.06.032 pmid:22813440.
112 Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148:1320-9.e3. doi:10.1053/j.gastro.2015.02.031 pmid:25724455.
113 Stein R, Lee D, Leonard MB, et al. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn’s Disease.Inflamm Bowel Dis 2016;22:1370-7. doi:10.1097/MIB.0000000000000769 pmid:27057683.
114 Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:444-7. doi:10.1016/j. cgh.2012.10.020 pmid:23103905.
115 Ashton JJ, Versteegh HP, Batra A, et al. Colectomy in pediatric ulcerative colitis: A single center experience of indications, outcomes, and complications. J Pediatr Surg 2016;51:277-81. doi:10.1016/j.jpedsurg.2015.10.077 pmid:26653944.
116 Gower-Rousseau C, Dauchet L, Vernier-Massouille G, et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol 2009;104:2080-8. doi:10.1038/ajg.2009.177 pmid:19436273.
117 Hyams JS, Davis P, Grancher K, Lerer T, Justinich CJ, Markowitz J. Clinical outcome of ulcerative colitis in children. J Pediatr 1996;129:81-8. doi:10.1016/S0022-3476(96)70193-2 pmid:8757566.
118 Soon IS, Wrobel I, deBruyn JC, et al. Postoperative complications following colectomy for ulcerative colitis in children. J Pediatr Gastroenterol Nutr 2012;54:763-8. doi:10.1097/MPG.0b013e318245265c pmid:22167014.
119 Pakarinen MP, Natunen J, Ashorn M, et al. Long-term outcomes of restorative proctocolectomy in children with ulcerative colitis. Pediatrics 2009;123:1377-82. doi:10.1542/peds.2008-2086 pmid:19403505.
120 Hansen LF, Jakobsen C, Paerregaard A, Qvist N, Wewer V. Surgery and postoperative recurrence in children with Crohn disease. J Pediatr Gastroenterol Nutr 2015; 60:347-51. doi:10.1097/MPG.0000000000000616 pmid:25373863.
121 Abdelaal K, Jaffray B. Colonic disease site and perioperative complications predict need for later intestinal interventions following intestinal resection in pediatric Crohn’s disease. J Pediatr Surg 2016;51:272-6. doi:10.1016/j.jpedsurg.2015.10.078 pmid:26653943.
122 Yoshida K, Fukunaga K, Ikeuchi H, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn’s disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis 2012;18:1617-23. doi:10.1002/ibd.21928 pmid:22081474.
123 Turner D, Griffiths AM. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis 2011;17:440-9. doi:10.1002/ibd.21383 pmid:20645317.
124 Lee D, Albenberg L, Compher C, et al. Diet in the pathogenesis and treatment of inflammatory bowel diseases. Gastroenterology 2015;148:1087-106. doi:10.1053/j.gastro.2015.01.007 pmid:25597840.
125 Obih C, Wahbeh G, Lee D, et al. Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within an academic IBD center. Nutrition 2016;32:418-25. doi:10.1016/j.nut.2015.08.025 pmid:26655069.
126 Lan A, Blachier F, Benamouzig R, et al. Mucosal healing in inflammatory bowel diseases: is there a place for nutritional supplementation? Inflamm Bowel Dis 2015;21:198-207. doi:10.1097/MIB.0000000000000177 pmid:25208104.
127 Knight-Sepulveda K, Kais S, Santaolalla R, Abreu MT. Diet and Inflammatory Bowel Disease.Gastroenterol Hepatol (N Y) 2015;11:511-20.pmid:27118948.
128 Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J Gastroenterol 2009;15:2570-8. doi:10.3748/wjg.15.2570 pmid:19496185.
129 Hwang C, Ross V, Mahadevan U. Micronutrient deficiencies in inflammatory bowel disease: from A to zinc. Inflamm Bowel Dis 2012;18:1961-81. doi:10.1002/ibd.22906 pmid:22488830.
130 Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters T, Griffiths A. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008;14:839-49. doi:10.1002/ibd.20378 pmid:18266237.
131 Griffiths AM, Wesson DE, Shandling B, Corey M, Sherman PM. Factors influencing postoperative recurrence of Crohn’s disease in childhood. Gut 1991;32:491-5. 
doi:10.1136/gut.32.5.491 pmid:2040470.
132 Bernstein CN, Artinian L, Anton PA, Shanahan F. Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity. Dig Dis Sci 1994;39:1638-41. doi:10.1007/BF02087769 pmid:8050312.
133 Dignass AU, Gasche C, Bettenworth D, et al. European Crohn’s and Colitis Organisation [ECCO]. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015;9:211-22. doi:10.1093/ecco-jcc/jju009 pmid:25518052.
134 Pappa HM, Gordon CM, Saslowsky TM, et al. Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics 2006;118:1950-61. doi:10.1542/peds.2006-0841 pmid:17079566.
135 Kabbani TA, Koutroubakis IE, Schoen RE, et al. Association of Vitamin D Level With Clinical Status in Inflammatory Bowel Disease: A 5-Year Longitudinal Study.Am J Gastroenterol 2016;111:712-9. doi:10.1038/ajg.2016.53 pmid:26952579.
136 Pappa H, Thayu M, Sylvester F, Leonard M, Zemel B, Gordon C. Skeletal health of children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011;53:11-25. doi:10.1097/MPG.0b013e31821988a3 pmid:21694532.
137 Pappa HM, Mitchell PD, Jiang H, et al. Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens. J Clin Endocrinol Metab 2012;97:2134-42. doi:10.1210/jc.2011-3182 pmid:22456619.
138 Sylvester FA, Gordon CM, Thayu M, et al. Report of the CCFA pediatric bone, growth and muscle health workshop, New York City, November 11-12, 2011, with updates.Inflamm Bowel Dis 2013;19:2919-26. doi:10.1097/MIB.0b013e3182a5a004 pmid:23974992.
139 Greenley RN, Hommel KA, Nebel J, et al. A meta-analytic review of the psychosocial adjustment of youth with inflammatory bowel disease. J Pediatr Psychol 2010;35:857-69. doi:10.1093/jpepsy/jsp120 pmid:20123705.
140 Gray WN, Boyle SL, Graef DM, et al. Health-related quality of life in youth with Crohn disease: role of disease activity and parenting stress. J Pediatr Gastroenterol Nutr 2015;60:749-53. doi:10.1097/MPG.0000000000000696 pmid:25564807.
141 Mackner LM, Greenley RN, Szigethy E, Herzer M, Deer K, Hommel KA. Psychosocial issues in pediatric inflammatory bowel disease: report of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2013;56:449-58. doi:10.1097/MPG.0b013e3182841263 pmid:23287808.
142 Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol 2014;12:1443-51, quiz e88-9.
doi:10.1016/j.cgh.2014.01.021 pmid:24462626.
143 de Ridder L, Turner D, Wilson DC, et al. Porto IBD Working Group of ESPGHAN. Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the
porto pediatric IBD group. Inflamm Bowel Dis 2014;20:291-300. 
doi:10.1097/01.MIB.0000439066.69340.3c pmid:24374875.
144 Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36-41. e1. doi:10.1016/j.cgh.2010.09.016 pmid:20888436.
145 Castano-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther 2014;39:645-59. doi:10.1111/
apt.12651 pmid:24612141.
146 Peneau A, Savoye G, Turck D, et al. Mortality and cancer in pediatric-onset inflammatory bowel disease: a population-based study. Am J Gastroenterol 2013;108:1647-53. doi:10.1038/ajg.2013.242 pmid:23939626.
147 Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228-33. doi:10.1056/NEJM199011013231802 pmid:2215606.
148 Noh SY, Oh SY, Kim SH, Kim HY, Jung SE, Park KW. Fifteen-year-old colon cancer patient with a 10-year history of ulcerative colitis. World J Gastroenterol 2013;19:2437-40. doi:10.3748/wjg.v19.i15.2437 pmid:23613641.
149 Rosen MJ, Dhawan A, Saeed SA. Inflammatory Bowel Disease in Children and Adolescents. JAMA Pediatr 2015;169:1053-60. doi:10.1001/ jamapediatrics.2015.1982 pmid:26414706.
150 Shergill AK, Lightdale JR, Bruining DH, et al. American Society for
Gastrointestinal Endoscopy Standards of Practice Committee. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 2015;81:1101-21.e1, 13.
doi:10.1016/j.gie.2014.10.030 pmid:25800660.
151 Annese V, Daperno M, Rutter MD, et al. European Crohn’s and Colitis Organisation. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013;7:982-1018. doi:10.1016/j.crohns.2013.09.016 pmid:24184171.
152 Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501-23, quiz 524.
doi:10.1038/ajg.2009.727 pmid:20068560.
153 Wang R, Leong RW. Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature. World J Gastroenterol 2014;20:8783-9.pmid:25083052.
154 Autenrieth DM, Baumgart DC. Toxic megacolon. Inflamm Bowel Dis 2012;18:584-91. doi:10.1002/ibd.21847 pmid:22009735.
155 Rahier JF, Magro F, Abreu C, et al. European Crohn’s and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014;8:443-68.
doi:10.1016/j.crohns.2013.12.013 pmid:24613021.
156 Rao K, Higgins PD. Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:1744-54.
doi:10.1097/MIB.0000000000000793 pmid:27120571.
157 Pascarella F, Martinelli M, Miele E, Del Pezzo M, Roscetto E, Staiano A. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr 2009;154:854-8. doi:10.1016/j.jpeds.2008.12.039 pmid:19230908.
158 Veereman-Wauters G, de Ridder L, Veres G, et al. ESPGHAN IBD Porto Group. Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group commentary.J Pediatr Gastroenterol Nutr 2012;54:830-7. doi:10.1097/MPG.0b013e31824d1438 pmid:22584748.
159 Ruemmele FM, Lachaux A, Cezard JP, et al. Groupe Francophone d’Hepatologie, Gastroenterologie et Nutrition Pediatrique. Efficacy of infliximab in pediatric Crohn’s disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis 2009;15:388-94. doi:10.1002/ibd.20788 pmid:19023899.
160 Crandall W, Hyams J, Kugathasan S, et al. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr 2009;49:183-90. doi:10.1097/MPG.0b013e3181a70f21 pmid:19561542.
161 de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr 2004;39:46-52. doi:10.1097/00005176-200407000-00010 pmid:15187780.
162 Kim MJ, Lee JS, Lee JH, Kim JY, Choe YH. Infliximab therapy in children with Crohn’s disease: a one-year evaluation of efficacy comparing ‘top-down’ and ‘step-up’ strategies. Acta Paediatr 2011;100:451-5. doi:10.1111/j.1651-2227.2010.01938.x pmid:20626362.
163 Schaefer ME, Machan JT, Kawatu D, et al. Factors that determine risk for
surgery in pediatric patients with Crohn’s disease. Clin Gastroenterol Hepatol
2010;8:789-94. doi:10.1016/j.cgh.2010.05.021 pmid:20566311.
164 Hait EJ, Bousvaros A, Schuman M, Shamberger RC, Lillehei CW. Pouch outcomes among children with ulcerative colitis treated with calcineurin inhibitors before ileal pouch anal anastomosis surgery. J Pediatr Surg 2007;42:31-4, discussion 34-5. doi:10.1016/j.jpedsurg.2006.09.006 pmid:17208537.
165 Dharmaraj R, Dasgupta M, Simpson P, Noe J. Predictors of Pouchitis After Ileal Pouch-Anal Anastomosis in Children. J Pediatr Gastroenterol Nutr 2016;63:e58-62. 
doi:10.1097/ MPG.0000000000001279 pmid:27243421.
166 Shen B, Remzi FH, Lavery IC, Lashner BA, Fazio VW. A proposed classification of ileal pouch disorders and associated complications after restorative proctocolectomy. Clin Gastroenterol Hepatol 2008;6:145-58, quiz 124. doi:10.1016/j.cgh.2007.11.006 pmid:18237865.
167 Schreiber S, Lawrance IC, Thomsen OO, Hanauer SB, Bloomfield R, Sandborn WJ. Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 2011;33:185-93. doi:10.1111/j.1365-2036.2010.04509.x pmid:21083671.
168 Feagan BG, Rutgeerts P, Sands BE, et al. GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710. doi:10.1056/NEJMoa1215734 pmid:23964932.
169 Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014;147:618-627.e3. doi:10.1053/j.gastro.2014.05.008 pmid:24859203.
170 Conrad MA, Stein RE, Maxwell EC, et al. Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:2425-31.
doi:10.1097/MIB.0000000000000918 pmid:27598742. 
171 Singh N, Rabizadeh S, Jossen J, et al. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:2121-6. doi:10.1097/MIB.0000000000000865 pmid:27542130.
172 Engel T, Kopylov U. Ustekinumab in Crohn’s disease: evidence to date and place in therapy. Ther Adv Chronic Dis 2016;7:208-14. doi:10.1177/2040622316653306 pmid:27433311.
173 Bishop C, Simon H, Suskind D, Lee D, Wahbeh G. Ustekinumab in Pediatric Crohn Disease Patients. J Pediatr Gastroenterol Nutr 2016;63:348-51. doi:10.1097/MPG.0000000000001146 pmid:26854655.
174 Rinawi F, Rosenbach Y, Assa A, Shamir R. Ustekinumab for Resistant Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2016;62:e34-5. doi:10.1097/MPG.0000000000000503 pmid:25023579.
175 Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P. Retic Study Group (Rifaximin-Eir Treatment in Crohn’s Disease). Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn’s disease. Gastroenterology 2012;142:473-481.e4. doi:10.1053/j.gastro.2011.11.032 pmid:22155172.

 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2021